New treatments being tested at Stanford Medicine offer hope for glaucoma patients who currently have no way to restore lost vision. While existing therapies can slow the disease's progression by lowering eye pressure, they cannot repair the optic nerve damage that causes blindness. Now, researchers are developing innovative approaches, including a tiny stem cell implant and gene therapies, that could prevent further vision loss and even restore sight to patients who thought their condition was permanent. What Is Glaucoma and Why Current Treatments Fall Short? Glaucoma damages the optic nerve, the bundle of fibers that transmits all visual information from the eye to the brain. It is the leading cause of irreversible vision loss and blindness worldwide. Current treatments focus on reducing abnormal pressure inside the eye through laser treatments, medicated eye drops, or surgery. However, these pressure-lowering approaches have significant limitations. Even with excellent access to care and the best available treatments, a substantial portion of glaucoma patients continue to lose vision. Up to 10% of people with glaucoma become resistant to standard treatments, and some patients progress to legal blindness despite receiving proper care. This gap in treatment effectiveness has created an urgent need for new therapeutic approaches that go beyond pressure control. How Are Researchers Developing New Vision-Restoring Therapies? Stanford Medicine researchers, led by Jeffrey Goldberg, MD, PhD, chair of ophthalmology, are pursuing three main categories of innovative treatments: - Stem Cell Implants: A tiny dumbbell-shaped implant, slightly longer than half a centimeter, is surgically placed in the eye's vitreous cavity, the gel-filled space between the lens and retina. The implant contains stem cells that secrete ciliary neurotrophic factor (CNTF), a naturally occurring growth factor that supports neuron growth and protects nerve cells from damage. - Gene Therapy: Researchers discovered that cells called astrocytes can either speed up or slow down glaucoma's progression depending on how they respond to the disease. Scientists developed a gene therapy that flips harmful astrocytes into helpful ones, preventing nerve damage and protecting vision in animal studies. - Electrical Stimulation and Growth Factor Delivery: Additional trials are testing electrical stimulation of the retina and growth factors delivered through eye drops to protect and potentially regenerate damaged nerve cells. These approaches represent a fundamental shift in glaucoma treatment philosophy. Rather than only slowing disease progression, researchers are now testing therapies that could actively protect remaining nerve cells and restore vision that has already been lost. What Do Early Clinical Trial Results Show? Goldberg's team recently completed a multicenter, randomized Phase 2 clinical trial of the stem cell implant device. The results demonstrated strong neuroprotective effects, meaning the implant successfully prevented severe vision loss caused by glaucoma. While the implant did not reverse vision loss in this smaller trial, the neuroprotective findings represent a significant step forward for patients who currently have no way to recover lost sight. The gene therapy research has shown even more promising results in animal studies. In a 2024 study published in Nature, researchers found that delivering gene therapy to the eyes of mice with glaucoma flipped harmful astrocytes to beneficial ones, thereby preventing nerve damage entirely. These findings suggest that combining multiple therapeutic approaches may offer the best outcomes for patients. "Even among patients with great access to care, a significant fraction of them will progress to legal blindness despite our best treatments. So, there's a significant unmet need," said Jeffrey Goldberg, chair of ophthalmology at Stanford Medicine. Jeffrey Goldberg, MD, PhD, Chair of Ophthalmology at Stanford Medicine When Might These Treatments Become Available to Patients? Goldberg envisions these new therapies as complementary to current treatments rather than replacements. He described the approach as a "belt-and-suspenders" strategy, where patients would receive both their traditional eye pressure-lowering therapy and newer neuroprotective or regenerative treatments. This combination approach could address glaucoma from multiple angles simultaneously, offering patients the best chance at preserving and potentially restoring vision. The research represents the first time in more than 20 years of studying glaucoma that the possibility of more effectively preventing vision loss, or even restoring lost vision, seems within reach. Goldberg noted that over the last decade, there has been a significant shift toward developing and testing new forms of therapy beyond pressure control, with advances moving from laboratory studies into human clinical trials. "Jeff is a world-recognized authority on neuroprotection to detect and prevent vision loss from glaucoma. His research on protecting and even replacing the retinal nerve cells that connect the eye to the brain could be a major breakthrough and effectively cure glaucoma," stated Thomas Brunner, president and CEO of the Glaucoma Research Foundation. Thomas Brunner, President and CEO of the Glaucoma Research Foundation What Should Glaucoma Patients Know Right Now? While these experimental therapies show promise, they are still in clinical trials and not yet available to the general public. However, patients interested in participating in ongoing research can explore clinical trial opportunities through Stanford Medicine's ophthalmology department. The key takeaway for people with glaucoma is that the field is rapidly evolving, and new treatment options that could restore vision are on the horizon. In the meantime, continuing to follow current treatment recommendations remains essential. Regular eye exams, consistent use of prescribed eye drops, and adherence to pressure-lowering treatments can slow or halt glaucoma's progression, especially when the disease is caught early. As these new therapies move through clinical trials, patients should discuss their individual situation with their eye care provider to understand both current treatment options and potential future opportunities.
